Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders ...

Acelyrin (NASDAQ:SLRN – Get Free Report) is projected to issue its quarterly earnings data before the market opens on ...

Drug development company Acelyrin Inc. recently saw a modest increase in its stock price after announcing the adoption of a ...

We recently published a list of 10 Best Short-Term Stocks To Buy Right Now. In this article, we are going to take a look at where Acelyrin, Inc.

Acelyrin has declined a surprise offer from Concentra Biosciences, and is instead pushing ahead with plans to merge with immune-mediated disease specialist Alumis. Los Angeles-based Acelyrin ...

ACELYRIN, INC. has announced that its Board of Directors has determined that an unsolicited proposal from Concentra Biosciences is unlikely to lead to a better offer than its planned all-stock ...

LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN) and Alumis Inc. (Nasdaq: ALMS) today reaffirmed their commitment to merge in an all ...

ACELYRIN, INC. LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of ...

Acelyrin (NASDAQ:SLRN) traded sharply lower on Tuesday after the company and its California-based rival Alumis (NASDAQ:ALMS) reaffirmed their commitment to merge in line with their previously ...

Information about ACELYRIN’s directors and executive officers is set forth in the proxy statement for ACELYRIN’s 2024 Annual Meeting of Stockholders, which was filed with the SEC on April 22 ...